Company Filing History:
Years Active: 2017-2023
Title: Bruce M Wentworth: Innovator in Antisense Oligonucleotide Technology
Introduction
Bruce M Wentworth is a notable inventor based in Northborough, MA (US), recognized for his contributions to the field of antisense oligonucleotide technology. He holds a total of five patents, showcasing his innovative approach to addressing complex medical challenges. His work primarily focuses on modulating the expression of glycogen synthase, which has significant implications for treating diseases such as Pompe disease.
Latest Patents
One of Wentworth's latest patents involves inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides. This patent details the use of antisense oligonucleotides (AONs) to modulate the expression of glycogen synthase, which can be beneficial in treating diseases associated with this enzyme. The patent also includes compositions comprising AONs and methods for downregulating mRNA coding for glycogen synthase, as well as methods for reducing glycogen synthase in skeletal and cardiac muscle. Another significant patent focuses on the conjugation of multiple phosphorodiamidate morpholino oligonucleotides (PMOs) to cationic cell-penetrating peptides (CPPs) to enhance the uptake of PMOs into skeletal and cardiac muscle cells.
Career Highlights
Throughout his career, Bruce M Wentworth has worked with prominent companies in the biotechnology sector, including Genzyme Corporation and Ionis Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.
Collaborations
Wentworth has collaborated with notable colleagues, including Carol A Nelson and Timothy E Weeden. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.
Conclusion
Bruce M Wentworth's innovative contributions to antisense oligonucleotide technology have the potential to transform the treatment of diseases like Pompe disease. His patents reflect a commitment to advancing medical science and improving patient outcomes.